

FY2026 Q1 FINANCIAL RESULTS **(Ended June 30, 2026)**

August 12, 2026

H.U. Group Holdings, Inc.

(TSE: 4544)

- ※ The financial information in this document follows Japanese GAAP, with the exception for EBITDA (Operating Profit + Depreciation + Goodwill Impairment), which is a non-GAAP measure.
- ※ In some cases, “Net profit/loss attributable to shareholders of the parent company” may be abbreviated as “Net profit/loss”.
- ※ Figures are generally rounded to the nearest whole number. As a result of rounding, there may be instances where the totals do not exactly match the sum of the individual figures.
- ※ Abbreviations:
 - IVD : In-Vitro Diagnostics
 - LTS : Lab Testing and its related Services
 - HS : Healthcare-related Services
- ※ Exchange rates in this report:
 - FY2025 Q1: 1 USD = 144.61 JPY 1 EURO = 163.80 JPY
 - FY2025 Q1: 1 USD = 159.48 JPY 1 EURO = 185.38 JPY

1. SUMMRY

EXECUTIVE SUMMARY (CONSOLIDATED)

(100 Million JPY)

NET SALES

626

EBITDA

72

EBITDA margin:
11.4%

OPERATING PROFIT

21

Operating profit margin:
3.4%

NET PROFIT

16

EPS

28.5 JPY

YoY

+12 / +1.9%

+9 / +13.6%

+12 / +141%

+28 / + --%

+50 / + --%

PROGRESS

24.4%

24.7%

23.3%

31.5%

31.6%

FY2026
FORECAST

2,560

290

90

50

90.1

EXECUTIVE SUMMARY (BY SEGMENT)


(100 Million JPY)

	NET SALES	EBITDA	OPERATING PROFIT	KEY POINTS
IVD YoY Progress	164 +23 / +16% 25.2%	39 +2 / +6.2% 23.7%	24 +1 / +5.6% 22.2%	- NEURO: Strong growth in the U.S. and Europe, driven by plasma assays (YoY +85%) - CDMO: YoY +20% - Lumipulse JPN: Base business (excl. COVID) remained stable
LTS YoY Progress	396 +3 / +0.8% 24.1%	39 +13 / +48% 25.1%	7 +15 / + --% 25.0%	- Genomic testing: Stable growth - Profit growth driven by pricing optimization and fixed-cost reductions - One-time cost recorded in FY25 Q1
HS YoY Progress	66 -14 / -17% 24.4%	7 -5 / -40% 27.3%	5 -2 / -31% 30.6%	- Sales and profit decreased due to deconsolidation of the welfare business - Sterilization business: Sales growth driven by price optimization


NET SALES / OP CHANGES (YoY)

(100 Million JPY)

NET SALES



OPERATING PROFIT





PERFORMANCE BY DISEASE AREA

(100 Million JPY)

FY2025 Q1

FY2026 Q1

■ Oncology ■ NEURO ■ Infectious ■ Others




NEURO and Oncology continue to drive growth across the Group

3 Core Growth Areas : 1. NEURO (IVD), 2. CDMO (IVD; Oncology), 3. Genomic Testing (LTS; Oncology)

ORDINARY PROFIT / NET PROFIT (YoY)


(100 Million JPY)

ORDINARY PROFIT

Major Non-Operating Factors

- Foreign exchange loss 5.7 and Equity-method investment loss 4.5 recorded only in Q1 FY25

NET PROFIT

Major Extraordinary Factors

- Gain on sale of non-current assets 2.4

BALANCE SHEET

(100 Million JPY)


BALANCE SHEET (YoY)

	March 31, 2026	June 30, 2026	Change		March 31, 2026	June 30, 2026	Change
Current assets	1,266	1,269	+3	Liabilities	1,300	1,284	-16
Cash and deposits	481	445	-36	Trade payables	203	204	+0
Trade receivables	470	487	+16	Interest-bearing debt	743	736	-8
Inventories	240	253	+12	Others	353	344	-9
Others	75	84	+10	Net assets	1,375	1,346	-28
Non-current assets	1,408	1,361	-47	Equity	1,373	1,345	-28
Tangible assets	654	632	-22	Shareholders' equity	1,202	1,167	-34
Intangible assets	397	377	-20	Accumulated other comprehensive income	172	178	+6
Investments and others	357	351	-5	Non-controlling interests	2	1	-0
Deferred assets	0	0	-0				
Total assets	2,675	2,630	-45	Total liabilities and net assets	2,675	2,630	-45

INTEREST-BEARING DEBT / NON-CURRENT ASSETS


(100 Million JPY)

Cash and Deposits & Interest-bearing Debt



Cash/Deposits
 Bonds
 Debt
 Lease debt
 — Net Cash


Non-current assets



Tangible assets
 Intangible assets
 Investments/Others

CASH FLOW (PAST THREE YEARS)

(100 Million JPY)




FCF increased driven by higher operating cash flow from IVD / LTS growth and controlled investing cash flow

2. DETAILS BY SEGMENT

IVD BUSINESS

(100 Million JPY)

QUARTERLY PERFORMANCE



*Total of Overseas Lumipulse (Other) and other products

YOY


	FY2025 Q1	FY2026 Q1	CHANGE	%
Net Sales	141	164	+23	+16.2%
Lumipulse	65	77	+12	+18.6%
Japan (base)	38	37	-0	-0.8%
Japan (COVID)	7	4	-3	-38.7%
Overseas (NEURO)	16	30	+14	+85.1%
Overseas (Others)	4	5	+1	+28.5%
CDMO	61	73	+12	+19.9%
Others	15	14	-1	-8.8%
EBITDA	36	39	+2	+6.2%
OP	23	24	+1	+5.6%

- NEURO and CDMO delivered strong growth (Combined YoY +34%)
 - Expected to remain key drivers of future IVD business growth
- Lumipulse Japan: Base business (excl. COVID) remained stable
- Operating profit: Increased by NEURO growth, offset by upfront investments for Lumipulse placements in Japan and new contract development activities
- FX impact: Sales +11.1, Operating profit +2.2

IVD BUSINESS: PROGRESS IN NEURO

(100 Million JPY)

NEURO



TOPICS

- Continued strong growth in the U.S. and Europe, driven by plasma assays
 - Sales growth of +85% YoY
 - pTau217 plasma assay received CE Mark in May 2026
- pTau217 gained significant recognition at AAIC2026 (London)
 - Expanding production capacity for the pTau217 plasma assay to more than 10 times current levels
 - Pipeline expansion beyond Alzheimer's disease with new assay development and commercialization initiatives




Fujirebio Booth at AAIC 2026

IVD BUSINESS: PROGRESS IN CDMO

(100 Million JPY)

CDMO



TOPICS

- CDMO (Existing): Solid growth, driven by China's recovery and sustained global market growth (YoY +15%)
- CDMO (New): Strong growth in high-growth markets, including China and India (YoY +158%)
 - Vitamin D raw material supply volume in H1 is expected to reach 10 times the full-year Lumipulse volume

For Reference: Development-to-manufacturing phase transfers are progressing as expected vs. March 2025


		March, 31 2025	March, 31 2026	Change
In production	Global	32	40	+8
	Regional	36	42	+6
In development	Global	23	16	-7
	Regional	25	19	-6

- PSG is progressing in line with the plan
New business opportunities generated through Group-wide CDMO partnership synergies

LTS BUSINESS

(100 Million JPY)

QUARTERLY PERFORMANCE



YoY

	FY2025 Q1	FY2026 Q1	CHANGE	%
Net sales	393	396	+3	+0.8%
Off-site	327	331	+4	+1.3%
Hospitals*	246	249	+3	+1.2%
Genomic tests	77	81	+4	+5.3%
Others	169	168	-1	-0.6%
GP/Health Checkup	81	82	+1	+1.3%
FMS/Branch	59	59	-0	-0.6%
Others	7	6	-1	-10.3%
EBITDA	26	39	+13	+48.2%
OP	-8	7	+15	-


- Genomic testing continued to grow steadily (YoY +5%)
- Pricing optimization progressed as planned, contributing to higher marginal profit, while fixed-cost reductions also supported operating profit growth
- Prior-year Q1 recorded approximately 0.9 billion JPY in one-time Akiruno-related expenses

*: Including sales come from alliance partners

LTS BUSINESS: PROGRESS IN GENOMIC TESTING

(100 Million JPY)

QUARTERLY PERFORMANCE



TOPICS


- Genomic testing continued stable growth
 - Higher testing demand expected for assays newly launched in FY2025
 - “HemSight®” Hematological malignancy gene panel
 - OncoGuide™ OncoScreen™ Plus CDx System
 - Existing assays
 - Oncotype DX Breast Recurrence Score
- Regulatory approval obtained for the “Fujinokuni HOPE OncoPanel®” a Comprehensive Genomic Profiling System (March 2026)
 - The only panel system, using Japanese cancer data*
 - Following reimbursement coverage, SRL will provide testing service to medical institutions nationwide

*: Among tests performed under reimbursement (as of August 2026)

HS BUISSNESS

(100 Million JPY)

QUARTERLY PERFORMANCE



YoY

	FY2025 Q1	FY2026 Q1	CHANGE	%
Net sales	80	66	-14	-17.4%
Sterilization/ operation-related	61	60	-1	-0.9%
In-hospital	46	46	+1	+1.6%
Outsourced	7	7	+0	+1.5%
Others	9	7	-1	-15.9%
Home-visiting	6	6	+0	+6.7%
Welfare	13	-	-	-
EBITDA	11	7	-5	-39.9%
OP	8	5	-2	-30.8%

- Sterilization/operation-related business
 - Sales increase by price optimization etc., mainly in in-hospital category
- Sales and profit declined due to the deconsolidation of the welfare business (Care'x)



Disclaimer regarding forward-looking statement:

The financial forecasts and forward-looking statements contained in this document are based on information currently available to the Company's management, as well as certain assumptions and judgments that involve inherent risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements due to various factors.

Factors that may affect actual results include, but are not limited to, deterioration in economic conditions, fluctuations in foreign exchange rates, changes in regulatory, legal, or administrative requirements, delays in the launch of new products, competitive pressures arising from competitors' product strategies, and declines in the sales performance of existing products.